by Ashley | May 4, 2021 | Clinical Trial, COVID-19, Press Release, Stem Cell
Just three months after the initial treatments, Personalized Stem Cells, Inc (PSC), a human adipose-derived stem cell company, announces enrollment is complete for COVID-19 FDA approved stem cell clinical trial licensed to Sorrento Therapeutics (Nasdaq: SRNE,...
by Ashley | Apr 30, 2021 | Blog, Clinical Trial, COVID-19
In February, we announced preliminary results in a COVID-19 stem cell clinical trial that we licensed to Sorrento Therapeutics. To give a bit of backstory for those who may be new to our blog, Personalized Stem Cells went to work in the early pandemic days to...
by Valet | Feb 4, 2021 | Clinical Trial, COVID-19, Press Release
Personalized Stem Cells, Inc (PSC), a human adipose-derived stem cell company, announces that the first patients have received stem cell therapy for the treatment of COVID-19 as part of an FDA approved clinical trial. The ongoing clinical trial and stem cell platform,...
by Ashley | Oct 16, 2020 | Blog, COVID-19, Personalized Stem Cells
Personalized Stem Cells is ‘Personalized’ for a reason. Our primary focus has always been on providing autologous adipose derived stem cell services to physicians for their patients. When the pandemic struck, however, we felt a call to action and our focus was...
by Ashley | Sep 18, 2020 | Blog, COVID-19, Personalized Stem Cells
A Call to Action As you may be aware, Personalized Stem Cells recently received approval to treat COVID-19 patients in a phase 1 clinical trial. When COVID-19 was declared a global pandemic, we immediately felt called to action. With almost two decades’ worth of...